Default Banner

Announcing a new National Accounts Manager, Christine Versichele.

In this role, Christine’s focus will be working directly with strategic multi-national and global accounts within the pharmaceutical compounding industry. This focus is consistent with DYNALABS’ business model for sustainable accelerated growth. We believe Christine’s vast industry knowledge and experience will serve her well in identifying new opportunities and developing cost-effective custom solutions. As National Account Manager, Christine will further promote DYNALABS’ guiding principles – Patient Safety, Affordable Healthcare, and Business Success – within the market place.



DYNALABS is pleased to announce Tim Johnson as Chief Technology Officer.

Tim has extensive technology, executive, and start-up experience in the health care, public, and technology sector. Tim will use that experience to help DYNALABS maintain our competitive advantage as technology leaders in our current and future market space.


DYNALABS is pleased to announce Kristopher Le as our new Principal Consultant.

In this role, Kris will provide greater focus on DYNALABS’ Consulting Practice with the goal of strengthening our current service offerings.

Kris joins DYNALABS with a wealth of experience and knowledge. He has held various roles in our industry, including licensed pharmacist and the Director of 503B Operations. Kris has experience in sterile and non-sterile compounding, developing SOPs and formulas as related to the compounding of sterile and non-sterile products, ensuring pharmacy compliance of state regulations and laws as well as USP <795> and USP <797> guidelines, assisting in the development of equipment/process validation programs, performing GAP analysis/audits to ensure cGMP and/or USP <797> compliance, initiation and maintenance of quality systems, and many other duties.


DYNALABS embarks on $1.2 million expansion

DYNALABS LLC, a St. Louis-based pharmaceuticals testing lab, is spending $1.2 million to expand its microbiology lab and office space, the company said.

The renovation, expected to be complete in the first quarter of 2018, will double capacity to relieve overcrowding and improve workflow, among other changes, officials said.


Link to Business Journal Ad >

DYNALABS announces Director of Quality & Regulatory Affairs

DYNALABS LLC is pleased to announce Nichole DiLorretta as our Director of Quality & Regulatory Affairs. Nichole is responsible for daily QA operations as well as corporate projects related to quality and regulatory compliance.

Nichole holds a Bachelor of Science in Biology, with an emphasis in Biochemistry from Southern Illinois University. She holds Forensic Science and Forensic Chemistry and Analysis certification from Saint Louis University.


 DYNALABS LLC Named One of Inc. 5000 Fastest-Growing Private Companies in 2017

ST. LOUIS – For the fourth time, DYNALABS LLC made the 2017 Inc. 5000 list of the fastest-growing private companies in America. Out of nearly 7 million private companies moving the economy forward every day, only a small fraction demonstrate remarkable and consistent high growth.

DYNALABS LLC is proud to have made this list again. DYNALABS continues to grow every day and impacts the economy and patients’ safety and lives.  It conducts all business with its guiding principles of patient safety, affordable healthcare, and business success on our mind.


DYNALABS Announces a New Vice President of Sales

DYNALABS is pleased to announce Bill Russell as our new Vice President of Sales to further develop and grow our business while following our Guiding Principles:

Bill Russell brings a wealth of experience to DYNALABS.  With over 20 years of sales and marketing experience, Bill has developed and driven sales in diverse business industries.  He has directed key initiatives, always ensuring alignment and collaboration among sales, technical, and operations staff to maximize sales results.


DYNALABS offers Low Concentration Oxytocin potency by Ultra High Performance Liquid Chromatography (UHPLC)

New Potency Testing Capability –  DYNALABS has transitioned from Liquid Chromatography/Mass Spectrometry for quantitation of Low Concentration Oxytocin and now has a stability indicating method of testing Low Concentration Oxytocin using Ultra High Performance Liquid Chromatography as low as 15mU/mL. The new method is more efficient method and provides more accurate results than LC/MS due to the reproducibility of the instrumentation which reduces the likelihood of system suitability issues.


DYNALABS Announces New President

We’re pleased to announce that Jun Fabella has accepted the position of President of DYNALABS.

For some time now, Jun has been leading the drive to expand our infrastructure with the goal of enhancing our efficiencies and processes. In doing so, he has been executing the DYNALABS’ philosophy of ‘relentless pursuit of excellence’.


DYNALABS Enhances Antimicrobial Effectiveness Testing for USP <51>

Through the continuing enhancement of our internal systems and sample receipt processes, the testing for USP <51> has seen a significant reduction of time in receiving these test results.

Antimicrobial Effectiveness testing is performed to determine the efficacy of preservatives within a compound against specific challenge organisms. DYNALABS’ AE testing procedure is based of USP chapter 51 guidelines. This test is used for testing multi-dose pharmaceuticals and products.

Testing for USP<51> requires Suitability Testing and will also require the preservative to be declared on the samples labeling. Required sample amount(s) for the the routine testing will be based upon the preservative indicated.

Continue Reading >

Custom Packing Slip

Improvements to our Test Request process
The DYNALABS’ online Test Request process will soon generate automatically a custom packing slip. You enter no additional data; the information needed for the packing slip has already been entered as part of the normal sample submission web pages; all you do is click on the ‘Submit and Print” button. The packing slip includes your client information, as well as all the information needed about the lots being submitted to DYNALABS.

Benefits of the new packing slip include the ability to receive your shipments more efficiently and quickly, and to process the requested tests more precisely.

Continue Reading >

DYNALABS Receives ISO/IEC 17025 Accreditationlogo_a2La

St. Louis, Missouri – DYNALABS is pleased to announce that the American Association for Laboratory Accreditation (A2LA) has approved our company for ISO/IEC 17025 accreditation. To gain the accreditation, DYNALABS underwent a thorough assessment of its quality management processes, and competency to perform analytical and microbiological testing on pharmaceutical raw materials and compounded drug products.


 DYNALABS LLC and a large North American hospital have signed an agreement to test their DVx™ against drug diversion.

Drug diversion, theft and unapproved usage of narcotic drugs, is a common problem in health care today. Since the DVx-04™ can identify such drugs, and also detect if they have been manipulated, the DVx-04 could be used as a possible tool to prevent this development. The interest in using the  DVx-04™ for this purpose has been strengthened in the recent past. After a period of negotiation, Dynalabs LLC has now signed an agreement with a large North American hospital for an evaluation of the DVx-04™ against drug diversion. The system will be installed very soon and the evaluation is expected to last up to 3 months.

Russell Odegard, MBA 2002 Entrepreneurial Spirit

pix-russel-thumbRussell Odegard graduated in 2002 with a MBA and has a BSc with specialization in Microbiology from the University of Alberta, Canada. Russell is the co-founder and managing partner of DYNALABS LLC, an internationally recognized contract laboratory and quality assurance service supplier to the hospital, pharmacy, and pharmaceutical marketplaces. Russell possesses over 30 years of experience that spans basic cancer research, product development, and operations and quality management in the medical diagnostic, life sciences and pharmacy industries. Over the course of his career, Russell has held executive-level positions in small start-ups as well as large corporations, and successfully launched two companies, coordinated the development and commercialization of over 700 products worldwide, and received two patents.

Russell, his business partner Michael Pruett, and their wives Lina Odegard and Leslie Compton-Pruett fund student scholarships at the St. Louis College of Pharmacy and at the University of Missouri-St. Louis. Russell serves on the Financial Advisory Board at UMSL, the MOBIO Board of Directors, and enjoys guest speaking at local colleges whenever he gets the chance.

In his spare time, Russell enjoys spending time with his children and grandchildren, exercising, riding motorcycles, and traveling with his wife Lina.

Read The UMSL Article >>>

Mayor Francis G. Slay delivers the Spirit of St. Louis Award to DYNALABS

DYNALABS received the Spirit of St. Louis Award presented by the Mayor of St. Louis, Mayor Francis G. Slay. This award was given in recognition of DYNALABS being one of the fastest growing business in the nation and showing remarkable innovations in the pharmaceutical industry. The demand and growth for analytical testing and consulting services from DYNALABS allowed the company to move from the incubator into it’s own headquarters at Chouteau Crossing.

House Majority Leader Eric Cantor Visits DYNALABS

ST. LOUIS, April 13, 2012 — House Majority leader Eric Cantor was in St. Louis this week to speak at the National Rifle Association (NRA) national conference. In addition to this event, he also wanted to have the opportunity to meet with an up and coming small business in St. Louis. A company that would represent the new “growth engine” for the American economy.